Fierce Biotech Chutes & Ladders Welcome to this week's Chutes & Ladders, our roundup of hirings, firings and retirings throughout the industry. Read More
Endpoints News Antonio Gualberto starts post-Kura career at Eisai subsidiary H3 Days after Kura Oncology announced the departure of co-founder Antonio Gualberto, we finally know where he wound up. Read More
STAT Up and down the ladder: The latest comings and goings Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Read More
BioSpace BioSpace Movers & Shakers H3, a subsidiary of Eisai Co., named Antonio Gualberto as its new CMO. Gualberto will oversee global clinical research &… Read More
The Pharma Letter Eisai subsidiary names Antonio Gualberto as CMO H3 Biomedicine, the USA-based precision medicine subsidiary of Japanese drugmaker Eisai, has named industry Read More
Fierce Biotech Eisai unit H3 Biomedicine poaches Kura Oncology founder as CMO Antonio Gualberto, M.D., Ph.D., helped found early-stage biotech Kura Oncology and ran its R&D as chief medical officer. Read More
BioPharm Insight H3 Biomedicine in active discussions for co-developing its cancer genomics programs – CEO H3 Biomedicine is in talks with pharma companies to co-develop one or more of its Phase I drugs that are… Read More
Boston Business Journal H3 Biomedicine to Begin Trials of First-Ever Gene-Splicing Cancer Drug Kendall Square-based cancer biotech H3 Biomedicine, created five years ago by Japanese drug firm Eisai, will bring its first drug… Read More
PharmaVOICE H3 Biomedicine’s Dr. Lihua Yu Honored in PharmaVOICE 100 In her position as VP, data science and information technology, at H3 Biomedicine, Lihua Yu, Ph.D., is driving the expanded… Read More
Boston Business Journal Foundation Medicine, H3 Biomedicine Partner to Develop Cancer Drugs A partnership announced today between two Cambridge companies, Foundation Medicine (Nasdaq: FMI) and H3 Biomedicine, is further evidence of the… Read More